M
Murray F. Brennan
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 933
Citations - 103528
Murray F. Brennan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Sarcoma & Soft tissue sarcoma. The author has an hindex of 161, co-authored 925 publications receiving 97087 citations. Previous affiliations of Murray F. Brennan include Rensselaer Polytechnic Institute & Columbia University.
Papers
More filters
Journal ArticleDOI
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer: Analysis of 1001 Consecutive Cases
TL;DR: There is a need for clearly defined and widely applicable clinical criteria for the selection of patients who may benefit from hepatic resection for metastatic colorectal cancer and studies of preoperative staging techniques or of adjuvant therapies should consider using such a score for stratification of patients.
Journal ArticleDOI
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Ronald P. DeMatteo,Jonathan J. Lewis,Denis H. Y. Leung,Salvinder S. Mudan,James M. Woodruff,Murray F. Brennan +5 more
TL;DR: Tumor size predicts disease-specific survival in patients with primary disease who undergo complete gross resection and investigational protocols are indicated to reduce the rate of recurrence after resections and to improve the outcome for patients with GIST.
Journal ArticleDOI
Impact of hospital volume on operative mortality for major cancer surgery.
TL;DR: The hypothesis that when complex surgical oncologic procedures are provided by surgical teams in hospitals with specialty expertise, mortality rates are lower is supported.
Journal ArticleDOI
Determinants of Long-Term Survival After Major Surgery and the Adverse Effect of Postoperative Complications
Shukri F. Khuri,Shukri F. Khuri,William G. Henderson,Ralph G. DePalma,Cecilia Mosca,Nancy A. Healey,Dharam J. Kumbhani,John L. Cameron,Jonathan L. Meakins,J. Hans Jeekel,Murray F. Brennan,Bruce H. Barraclough +11 more
TL;DR: The occurrence of a 30-day postoperative complication is more important than preoperative patient risk and intraoperative factors in determining the survival after major surgery in the VA.
Journal ArticleDOI
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
TL;DR: Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.